We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) has announced that the late-stage study COSMIC-313 met its primary endpoint.
COSMIC-313 is an ongoing phase III study evaluating the combination of Cabometyx (cabozantinib), Bristol Myers’ (BMY - Free Report) Opdivo (nivolumab) and Yervoy (ipilimumab) versus the combination of Opdivo and Yervoy in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC).
The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall survival (OS). Exelixis is funding the study, and Bristol Myers is providing Opdivo and Yervoy for use in this study.
Cabometyx, in combination with Opdivo and Yervoy, significantly reduced the risk of disease progression or death compared with the combination of Opdivo and Yervoy. The study demonstrated significant improvement in PFS at the primary analysis.
However, at a prespecified interim analysis for the secondary endpoint of OS, the combination of Cabometyx, Opdivo and Yervoy versus the combination of Opdivo and Yervoy did not demonstrate a significant benefit and the study will continue to the next analysis of OS.
Exelixis intends to discuss the results with the FDA to determine the next steps toward a potential regulatory submission for the combination regimen for patients with previously untreated advanced intermediate- or poor-risk RCC.
Shares have gained 12.6% in the year so far against the industry’s decline of 20.3%.
Image Source: Zacks Investment Research
Exelixis’ lead drug Cabometyx, approved for treating patients with RCC and patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar, aids the company’s momentum amid stiff competition.
Additional label expansions will further boost growth.
In particular, the approval of Cabometyx for patients with advanced RCC as a first-line treatment in combination with Opdivo has fueled sales of the drug.
Bristol-Myers’ Opdivo is one of the leading revenue generators of the company and is approved for various oncology indications.
Cabometyx is also approved for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Other candidates in Exelixis’ pipeline include XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody-drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex.
Exelixis is looking to build a differentiated next-generation pipeline in oncology through strategic collaborations. The successful development of additional candidates will diversify its revenue base and reduce dependence on lead drug.
Competition is stiff in the RCC space, and capturing additional market share might become tough for Exelixis.
Merck’s (MRK - Free Report) Keytruda, in combination with Pfizer’s (PFE - Free Report) Inlyta, is also indicated for the first-line treatment of patients with advanced RCC.
Merck’s Keytruda, an anti-PD-1 therapy, is approved for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions.
Pfizer’s Inlyta has shown strong performance, driven by continued adoption in the United States and Europe. PFE’s older drug Sutent is also approved for advanced RCC.
Image: Bigstock
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
Exelixis, Inc. (EXEL - Free Report) has announced that the late-stage study COSMIC-313 met its primary endpoint.
COSMIC-313 is an ongoing phase III study evaluating the combination of Cabometyx (cabozantinib), Bristol Myers’ (BMY - Free Report) Opdivo (nivolumab) and Yervoy (ipilimumab) versus the combination of Opdivo and Yervoy in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC).
The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall survival (OS). Exelixis is funding the study, and Bristol Myers is providing Opdivo and Yervoy for use in this study.
Cabometyx, in combination with Opdivo and Yervoy, significantly reduced the risk of disease progression or death compared with the combination of Opdivo and Yervoy. The study demonstrated significant improvement in PFS at the primary analysis.
However, at a prespecified interim analysis for the secondary endpoint of OS, the combination of Cabometyx, Opdivo and Yervoy versus the combination of Opdivo and Yervoy did not demonstrate a significant benefit and the study will continue to the next analysis of OS.
Exelixis intends to discuss the results with the FDA to determine the next steps toward a potential regulatory submission for the combination regimen for patients with previously untreated advanced intermediate- or poor-risk RCC.
Shares have gained 12.6% in the year so far against the industry’s decline of 20.3%.
Image Source: Zacks Investment Research
Exelixis’ lead drug Cabometyx, approved for treating patients with RCC and patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar, aids the company’s momentum amid stiff competition.
Additional label expansions will further boost growth.
In particular, the approval of Cabometyx for patients with advanced RCC as a first-line treatment in combination with Opdivo has fueled sales of the drug.
Bristol-Myers’ Opdivo is one of the leading revenue generators of the company and is approved for various oncology indications.
Cabometyx is also approved for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Other candidates in Exelixis’ pipeline include XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody-drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex.
Exelixis is looking to build a differentiated next-generation pipeline in oncology through strategic collaborations. The successful development of additional candidates will diversify its revenue base and reduce dependence on lead drug.
Competition is stiff in the RCC space, and capturing additional market share might become tough for Exelixis.
Merck’s (MRK - Free Report) Keytruda, in combination with Pfizer’s (PFE - Free Report) Inlyta, is also indicated for the first-line treatment of patients with advanced RCC.
Merck’s Keytruda, an anti-PD-1 therapy, is approved for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions.
Pfizer’s Inlyta has shown strong performance, driven by continued adoption in the United States and Europe. PFE’s older drug Sutent is also approved for advanced RCC.
Exelixis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.